The Centralized Protocol and Data Management Unit (CPDMU) is a Cancer Center Shared Resource widely used by members performing clinical and translational trials. The CPDMU, which was formerly known as the Clinical Trials Office at the last CCSG review, plays a central role in clinical/translational research in the Cancer Center. The primary mission of the CPDMU is to provide the necessary components and support to conduct high-quality clinical cancer research at the Cancer Center at the University of Nebraska Medical Center, as well as UNMC affiliated hospitals (The Nebraska Medical Center, Children's Hospital Medical Center, Veterans Administration Hospital), and at Cancer Center Affiliate sites across the state. The CPDMU provides a centralized resource to facilitate the development, conduct, quality assurance monitoring, compliance with regulatory agency requirements, and evaluation of clinical research at the Cancer Center. All cancer related research proposals flow through the protocol development process established and administered by the CPDMU and are subsequently sent for review to the Protocol Review and Monitoring System (PRMS), the PRMS Scientific Review Committee (SRC) and to the IRB. The CPDMU database of clinical trials also provides support for the PRMS SRC and Audit Committee (AC) and for the Data and Safety Monitoring Committee (DSMC).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA036727-27
Application #
8566900
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
27
Fiscal Year
2013
Total Cost
$64,482
Indirect Cost
$21,060
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Barkeer, Srikanth; Chugh, Seema; Karmakar, Saswati et al. (2018) Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. BMC Cancer 18:1157
Cserhati, Matyas F; Mooter, Mary-Ellen; Peterson, Lauren et al. (2018) Motifome comparison between modern human, Neanderthal and Denisovan. BMC Genomics 19:472
Napon, Geoffroy; Dafferner, Alicia J; Saxena, Ashima et al. (2018) Identification of Carboxylesterase, Butyrylcholinesterase, Acetylcholinesterase, Paraoxonase, and Albumin Pseudoesterase in Guinea Pig Plasma through Nondenaturing Gel Electrophoresis. Comp Med 68:367-374
Luan, Haitao; Mohapatra, Bhopal; Bielecki, Timothy A et al. (2018) Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer Res 78:2524-2535
Rana, Sandeep; Sonawane, Yogesh A; Taylor, Margaret A et al. (2018) Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorg Med Chem Lett 28:3736-3740
Azadmanesh, Jahaun; Borgstahl, Gloria E O (2018) A Review of the Catalytic Mechanism of Human Manganese Superoxide Dismutase. Antioxidants (Basel) 7:
Haney, Staci L; Chhonker, Yashpal S; Varney, Michelle L et al. (2018) Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor. Invest New Drugs 36:810-818
Chhonker, Yashpal S; Haney, Staci L; Matthiesen, Robert A et al. (2018) Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: Derivatization and application. J Pharm Biomed Anal 153:22-28
Lockridge, Oksana; David, Emilie; Schopfer, Lawrence M et al. (2018) Purification of recombinant human butyrylcholinesterase on Hupresin®. J Chromatogr B Analyt Technol Biomed Life Sci 1102-1103:109-115
Saxena, Sugandha; Hayashi, Yuri; Wu, Lingyun et al. (2018) Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. Oncotarget 9:5931-5943

Showing the most recent 10 out of 1372 publications